• Risk assessment in Alzheimer’s disease
About genoSCORE™-LAB

genoSCORE™-LAB is a new non-invasive test that can predict the risk of an individual developing Alzheimer’s disease from a simple saliva sample. 

Initial applications will be for physicians assessing new patients, with cognitive complaints, to better understand their future risk of cognitive decline due to Alzheimer’s disease. It can also provide greater insight into the risk of cognitive decline in existing patients. 

Additionally, genoSCORE-LAB will be used in clinical study recruitment strategies to identify patients most suitable to enter trials of investigational Alzheimer’s drugs, including those patients with mild cognitive impairment who are most at risk of subsequent decline within the timescale of the study.

genoSCORE-LAB only requires a blood or saliva sample. An easy-to-use mouth swab enables individuals to provide a sample from home if they are self-isolating due to COVID-19, or not wishing or easily able to attend a healthcare setting.

genoSCORE-LAB is a genetic test, that analyses patient genotypes generated from an array of over 100,000 single nucleotide polymorphisms – common genetic variations - that are associated with, or protective against, the risk of developing Alzheimer’s disease. 

More specifically genoSCORE-LAB generates a polygenic risk score – generated through an algorithm, assessing multiple genetic loci and their associated disease-causing weights, alongside age and sex, which also affect risk. 

APOE status remains a major genetic component of risk in Alzheimer’s disease , especially carriers of the -E4 allele. However, genoSCORE-LAB provides additional information on the genetic risk of cognitive decline in the E4 heterozygote and E3 homozygote groups. 

genoSCORE-LAB will also report on APOE status, and highlight presence of gene variants known to be associated with Early Onset Alzheimer's disease.  

 

 

Patients and carers

This test will help you and your physician to better understand your risk of cognitive decline due to Alzheimer's disease. At this time the test has only been validated for people of European ancestry.

A sample of your DNA is collected through either a mouth swab or blood test, and analysed against over 100,000 specific variants in your DNA associated with Alzheimer’s disease. The readout from the test also encompasses your age and sex. 

The test will also report on APOE status – a known risk factor in Alzheimer's – and highlight any gene variants known to be associated with Early Onset Alzheimer's disease.  

Only your physician can order the genoSCORE™-LAB for you.

Contact us:
Cytox Ltd
Phone
Email

genoSCORE-LAB is developed and marketed by Cytox Ltd. For more information please visit our website www.cytoxgroup.com

+44 1865 986 226
Thank you. Your message has been sent to us.
Error! There was an error sending your message.